U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Mn.O4S.4H2O
Molecular Weight 223.062
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGANOUS SULFATE TETRAHYDRATE

SMILES

O.O.O.O.[Mn++].[O-]S([O-])(=O)=O

InChI

InChIKey=CDUFCUKTJFSWPL-UHFFFAOYSA-L
InChI=1S/Mn.H2O4S.4H2O/c;1-5(2,3)4;;;;/h;(H2,1,2,3,4);4*1H2/q+2;;;;;/p-2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula O4S
Molecular Weight 96.063
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Mn
Molecular Weight 54.938045
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Manganese Bromide is a highly water soluble crystalline salt composed of manganese and bromine with the formula MnBr2. Manganese Bromide can be used in place of palladium in the Stille reaction, which couples two carbon atoms using an organotin compound

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Manganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese.
Primary
Unknown

Approved Use

Manganese is used for weak bones (osteoporosis).
Palliative
Unknown

Approved Use

Early research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension.
Curative
MANGANESE SULFATE

Approved Use

Manganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Primary
MANGANESE SULFATE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Top-Down Strategy to Synthesize Mesoporous Dual Carbon Armored MnO Nanoparticles for Lithium-Ion Battery Anodes.
2017-04-12
Intramolecular Aminoalkoxylation of Unfunctionalized Olefins via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence.
2017-04-07
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats.
2016-11
Yolk-Shell MnO@ZnMn2 O4 /N-C Nanorods Derived from α-MnO2 /ZIF-8 as Anode Materials for Lithium Ion Batteries.
2016-10
Controlled Synthesis of Hollow Manganese Oxide Nanocrystals.
2016-02
Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics.
2014-05
Expression profile analysis of antioxidative stress and developmental pathway genes in the manganese-exposed intertidal copepod Tigriopus japonicus with 6K oligochip.
2013-08
Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.
2009-09
Manganese inhalation by rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity.
2007-06
CsR(R(6)CoI(12))2 (R = Gd, Er) and (CeI)0.26(Ce(6)MnI(9))2: two new structure types featuring R(6)Z clusters.
2006-11-27
Decreased expression of inflammation-related genes following inhalation exposure to manganese.
2006-05
Alterations of oxidative stress biomarkers due to in utero and neonatal exposures of airborne manganese.
2006
Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation.
2005-05
Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism.
2005-03
Bi- and poly-metallic cyanide-bridged complexes of the redox-active cyanomanganese nitrosyl unit [Mn(CN)(PR3)(NO)(eta-C5H4Me)].
2004-02-21
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin.
2003-01
Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate.
2002-09
Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative?
2002-07-31
Tetraaqua(1,10-phenanthroline-kappa(2)N,N')manganese(II) sulfate dihydrate.
2002-07
Differential ability of transition metals to induce pulmonary inflammation.
2001-11-15
Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions.
2001-06-18
Manganese citrate chemistry: syntheses, spectroscopic studies, and structural characterizations of novel mononuclear, water-soluble manganese citrate complexes.
2000-09-04
Manganese: brain transport and emerging research needs.
2000-06
Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators.
1999-03-01
Transformation of BALB/c-3T3 cells: IV. Rank-ordered potency of 24 chemical responses detected in a sensitive new assay procedure.
1993-07
Dietary calcium and manganese effects on menstrual cycle symptoms.
1993-05
Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants.
1985-02
Effect of fluoride on copper, manganese and zinc in bone and kidney.
1981-03
Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk.
1979-12
Cytochrome oxidase determination using a manganese citrate complex.
1970
Patents

Sample Use Guides

Broiler chicks:A basal corn-soybean meal diet (35 ppm Mn) was supplemented with 40, 80, or 120 ppm Mn from Manganese monoxide and fed ad libitum for 21 days.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Naked Manganese monoxide (MnO) nanoparticles had the cytototoxic effect with IC50 value more than 0.1 mg/ml in BRL 3A rat liver cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:00:40 GMT 2025
Edited
by admin
on Mon Mar 31 21:00:40 GMT 2025
Record UNII
F46LH60L4M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANGANOUS SULFATE TETRAHYDRATE
Common Name English
MANGANESE SULFATE TETRAHYDRATE
WHO-DD  
Preferred Name English
SULFURIC ACID, MANGANESE(2+) SALT, HYDRATE (1:1:4)
Common Name English
MANGANESE SULFATE (MNSO4) TETRAHYDRATE
Common Name English
MANGANESE SULPHATE TETRAHYDRATE
Systematic Name English
C.I. 77752
Common Name English
MANGANESE(2+) SULFATE TETRAHYDRATE
Systematic Name English
Manganese sulfate tetrahydrate [WHO-DD]
Common Name English
SULFURIC ACID, MANGANESE(2+) SALT (1:1), TETRAHYDRATE
Common Name English
Code System Code Type Description
MESH
C039798
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
SMS_ID
100000092428
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
PUBCHEM
22572548
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
EPA CompTox
DTXSID001015565
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
CHEBI
86358
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
CAS
10101-68-5
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
EVMPD
SUB22643
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
FDA UNII
F46LH60L4M
Created by admin on Mon Mar 31 21:00:40 GMT 2025 , Edited by admin on Mon Mar 31 21:00:40 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE